Moneycontrol
Last Updated : May 09, 2018 10:54 AM IST | Source: Moneycontrol.com

Suven Life Sciences gains 2% on securing product patents in Australia, Eurasia, Europe

The company has been granted 1 product patent each from Australia, Eurasia and Europe corresponding to the new chemical entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034.

Moneycontrol News @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Suven Life Sciences gained nearly 2 percent intraday Wednesday as company secured product patents in Australia, Eurasia and Europe.

The company has been granted 1 product patent each from Australia, Eurasia and Europe corresponding to the new chemical entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034.

The granted claims of the patents include the class of selective 5-HT4 compound.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.

A meeting of board of directors will be held on May 15, 2018 to consider the audited financial results for the fourth quarter and for the year ended March 31, 2018.

At 10:31 hrs Suven Life Sciences was quoting at Rs 186.00, up Rs 1.55, or 0.84 percent on the BSE.

Posted by Rakesh Patil
First Published on May 9, 2018 10:52 am
Loading...
Sections
Follow us on
Available On